Kiniksa Pharmaceuticals International, plc (KNSA)

NASDAQ | Biotech | Biopharmaceuticals for inflammatory diseases
Intro rate Introductory pricing for early customers through June 30 — the same full analysis at a lower rate while we refine delivery.
Free
No email, no account, no signup.
Pulling latest news for Kiniksa Pharmaceuticals International, plc…
Bull
Bear
Preliminary read — single AI model with live web search. The deep report cross-checks four models and more sources.
Intro rate Introductory pricing for early customers through June 30 — the same full analysis at a lower rate while we refine delivery.

Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.

Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – $4.99 $1.25
Order analysis – $4.99 $1.25

Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.

Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Biopharmaceuticals for inflammatory diseases
Market Cap
$4.4B
We're already tracking Kiniksa Pharmaceuticals International, plc — here are the latest events we've registered

Recent News

  • On April 28, 2026, Kiniksa reported Q1 2026 financial results with revenue of $214.3 million and raised its full-year net revenue guidance for ARCALYST. The company also announced that Phase 2 data for its KPL-387 program is expected in the second half of 2026.
Want to know how this news affects Kiniksa Pharmaceuticals International, plc? Order the analysis.
Order analysis – $4.99 $1.25

What you get

A complete express analysis — not just a signal. Delivered as a webpage in your account.

  • Signal: BUY / HOLD / SELL — with clear reasoning
  • Sentiment score 1–10 based on news, reports, and market data
  • Risk score 1–10 (dilution, jurisdiction, execution)
  • Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
  • Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
  • Upcoming catalysts with dates
  • Sources: news, filings, market data, and investor forums
  • Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Kiniksa Pharmaceuticals International, plc will be delivered in the same format.

Sample analyses in the same sector

Click to see what a complete analysis looks like.

Swedish Orphan Biovitrum AB (publ)
SOBI
HOLD
Revolution Medicines, Inc.
RVMD
BUY
Hansa Biopharma AB (publ)
HNSA
HOLD
Genovis AB (publ.)
GENO
NEUTRAL
Liquidia Corporation
LQDA
BUY
Order analysis – $4.99 $1.25
Not satisfied? Get your money back within 7 days — no questions asked.
Kiniksa Pharmaceuticals International, plc (KNSA)
Fresh analysis on demand
Buy express analysis – $4.99 $1.25
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.